Fate Therapeutics

Fate Therapeutics presented preclinical data for FT836, a CAR T-cell product targeting MICA/B proteins, at the 2024 SITC Annual Meeting, demonstrating robust anti-tumor activity across solid tumors and potential for combination therapies.

The global induced pluripotent stem cells (iPSCs) market, valued at USD 1.88 billion in 2023, is projected to grow to USD 4.48 billion by 2032, driven by advancements in regenerative and personalized medicine, drug discovery, and increased investments in stem cell research. Key market participants focus on improving iPSC generation methods, while challenges include high production costs, ethical issues, and regulatory complexities. North America leads the market, with Asia-Pacific showing rapid growth.